follow
success
vaccin
research
develop
r
respons
ebola
epidem
grobusch
goorhui
world
health
organ
priorit
epidem
infecti
diseas
eid
like
caus
sever
outbreak
near
futur
vaccin
prevent
eid
outbreak
becom
humanitarian
crise
cepi
kieni
et
al
howev
market
incent
fail
sustain
r
effort
area
plotkin
new
entiti
coalit
epidem
prepared
innov
cepi
set
us
billion
invest
target
support
develop
vaccin
contribut
world
prepared
eid
outbreak
cepi
one
cepi
first
busi
plan
target
advanc
develop
two
three
vaccin
candid
prioriti
eid
preclin
end
earli
clinic
safeti
immunogen
test
phase
iia
cepi
cepi
aim
address
r
prepared
gap
associ
lack
phase
eid
vaccin
advanc
epidem
outbreak
like
funder
pharmaceut
r
cepi
face
challeng
priorit
limit
resourc
order
meet
inher
riski
r
target
aurentz
kirschbaum
thuneck
evid
suggest
averag
probabl
success
advanc
vaccin
candid
preclin
end
phase
ii
less
pronker
weenen
commandeur
claassen
osterhau
addit
larg
cost
dimasi
grabowski
hansen
gougla
et
al
long
timelin
russel
gronwal
involv
develop
vaccin
make
invest
decis
space
tremend
complex
complex
compound
fact
commerci
object
lack
field
eid
vaccin
commerci
valu
alon
insuffici
criterion
make
pharmaceut
r
invest
decis
antonijev
cioff
pibouleau
phillip
bana
e
costa
address
busi
plan
target
line
mission
scope
cepi
launch
competit
call
propos
cfp
late
januari
support
develop
vaccin
r
three
prioriti
eid
lassa
viru
middl
east
respiratori
syndrom
coronaviru
nipah
viru
rational
invest
vaccin
r
project
would
improv
likelihood
gener
vaccin
relev
use
respons
eid
well
improv
likelihood
platform
technolog
support
vaccin
would
suitabl
use
vaccin
develop
newli
unexpectedli
emerg
eid
evalu
propos
receiv
respons
call
face
sever
challeng
first
pharmaceut
r
portfolio
manag
involv
consid
multipl
criteria
includ
organiz
capabl
technic
manufactur
feasibl
develop
timelin
cost
align
target
product
profil
tpp
aurentz
et
al
nickisch
seget
instanc
advoc
use
ideal
tpp
prefer
product
characterist
ppc
tailor
eid
outbreak
prepared
need
determin
use
potenti
vaccin
guid
r
prioriti
field
second
stakehold
opinion
vari
rel
import
differ
object
cepi
board
ultim
author
cepi
r
invest
independ
scientif
advisori
committe
sac
advis
cepi
board
secretariat
r
invest
make
technic
recommend
project
fund
composit
sac
divers
time
deliber
describ
includ
nine
repres
govern
regul
seven
industri
member
eight
academ
four
repres
r
organ
cepi
context
multipl
heterogen
stakehold
perspect
decis
analysi
mcda
potenti
improv
qualiti
decis
make
marsh
et
al
viergev
gougla
tromp
mcda
becom
increasingli
popular
health
valuat
marsh
et
al
thokala
et
al
applic
numer
across
varieti
area
health
adunlin
diabi
xiao
associ
decis
problem
drake
de
hart
monleon
toro
valentim
marsh
et
al
thokala
et
al
mcda
offer
ration
transpar
approach
prioriti
set
simultan
consid
relev
criteria
avoid
ad
hoc
decis
baltussen
niessen
multipl
stakehold
divers
perspect
mcda
make
relev
conflict
explicit
help
decis
maker
understand
consid
impact
decis
phillip
bana
e
costa
timmi
black
rappuoli
use
mcda
increasingli
advoc
vaccin
r
barrochi
black
rappuoli
timmi
et
al
howev
knowledg
one
mcda
framework
appli
support
priorit
vaccin
r
see
instanc
phelp
et
al
kloeber
madhavan
et
al
madhavan
et
al
madhavan
et
al
framework
place
emphasi
differ
attribut
burden
diseas
difficult
appli
cepi
context
given
sporad
unpredict
natur
eid
moreov
lend
easili
estim
valu
vaccin
r
adjust
probabl
success
po
earli
stage
riski
vaccin
candid
assum
sourc
prefer
constraint
relev
cepi
decis
context
mcda
framework
develop
accord
ispor
good
practic
guidelin
marsh
et
al
inform
priorit
eid
vaccin
r
propos
support
cepi
cfp
decis
test
sac
recommend
studi
report
applic
mcda
framework
result
anonym
confidenti
restrict
associ
ongo
contract
negoti
cepi
develop
select
propos
fund
analysi
focus
full
propos
select
cepi
sac
extend
review
follow
initi
review
preliminari
propos
cepi
propos
combin
budget
us
million
review
cepi
march
may
seventeen
propos
preclin
develop
phase
one
propos
clinic
phase
aim
cepi
fund
would
advanc
end
clinic
phase
propos
cover
three
differ
type
diseas
lassa
mer
nipah
propos
budget
rang
us
million
us
million
median
cost
us
million
propos
timefram
end
clinic
phase
rang
year
median
timefram
year
due
confidenti
restrict
individu
propos
budget
timefram
report
howev
budget
timefram
use
gener
valu
framework
present
propos
name
diseas
classif
anonym
throughout
remaind
manuscript
propos
label
platform
type
label
seven
propos
cover
diseas
seven
propos
cover
diseas
four
propos
cover
diseas
goal
undertak
quantit
valuat
rank
propos
criteria
interest
sac
assum
propos
could
fund
given
resourc
avail
remaind
section
provid
overview
model
approach
adopt
detail
provid
data
step
framework
octob
decemb
long
list
potenti
valu
criteria
initi
gener
via
document
review
includ
cepi
busi
plan
cepi
document
cepi
consult
inform
busi
plan
et
al
cepi
polici
document
principl
equit
access
cost
coverag
risk
share
manag
intellectu
properti
cepi
blueprint
process
evalu
criteria
use
agenc
health
r
fund
europ
unit
biomed
advanc
research
develop
author
barda
innov
medicin
initi
imi
horizon
ec
nation
aid
agenc
support
product
develop
partnership
activ
global
health
r
dfid
gougla
plaht
nea
addit
contribut
list
came
interview
member
sac
conduct
parallel
document
review
process
narrow
list
criteria
combin
criteria
valu
framework
member
sac
cepi
secretariat
staff
ask
first
email
survey
group
discuss
januari
determin
whether
factor
relev
cfp
decis
captur
criteria
relationship
criteria
whether
criteria
remov
overlap
irrelev
follow
engag
overal
valu
vi
estim
describ
equat
vi
overal
valu
propos
likelihood
gener
suitabl
vaccin
one
cfp
target
pathogen
likelihood
platform
technolog
suitabl
vaccin
develop
new
pathogen
weight
given
likelihood
gener
suitabl
vaccin
one
target
pathogen
weight
given
likelihood
platform
technolog
suitabl
vaccin
develop
new
pathogen
partial
valu
function
likelihood
gener
suitabl
vaccin
one
target
pathogen
partial
valu
function
likelihood
platform
technolog
suitabl
vaccin
develop
new
pathogen
ti
timefram
propos
deliv
r
discount
rate
number
criteria
identifi
defin
propos
perform
equat
describ
perform
criteria
combin
multipl
estim
propos
criteria
defin
tabl
criteria
defin
probabl
measur
scale
experi
likelihood
applic
suffici
compet
deliv
propos
activ
project
given
propos
feasibl
likelihood
develop
candid
vaccin
phase
ii
technic
feasibl
given
propos
manufactur
scalabl
speed
likelihood
vaccin
candid
manufactur
scalabl
timefram
volum
respond
outbreak
given
propos
use
potenti
cfp
target
pathogen
vaccin
candid
success
develop
manufactur
likelihood
meet
cepi
target
product
profil
relev
use
emerg
given
propos
use
potenti
new
pathogen
vaccin
candid
success
develop
manufactur
likelihood
platform
technolog
support
candid
vaccin
suitabl
use
vaccin
develop
newli
emerg
pathogen
given
propos
valu
framework
present
equat
present
approv
sac
februari
togeth
propos
criteria
descript
measur
scale
apprais
question
review
see
tabl
criteria
present
relat
probabl
vaccin
candid
technolog
platform
support
develop
success
advanc
end
clinic
phase
criteria
relat
anticip
benefit
propos
success
develop
end
clinic
phase
specif
criterion
relat
anticip
clinic
oper
benefit
vaccin
candid
respons
outbreak
target
diseas
candid
vaccin
success
develop
end
clinic
phase
criterion
relat
anticip
potenti
technolog
platform
use
develop
candid
vaccin
support
develop
candid
vaccin
newli
unexpectedli
emerg
pathogen
outbreak
regardless
whether
develop
vaccin
candid
current
target
pathogen
success
assum
technolog
platform
success
develop
valu
potenti
use
develop
vaccin
target
pathogen
depend
potenti
use
develop
vaccin
unknown
pathogen
vice
addit
valuabl
howev
either
potenti
realiz
platform
need
success
develop
reflect
criteria
moreov
valu
platform
technic
feasibl
vaccin
develop
compet
develop
vaccin
manufactur
scale
platform
platform
potenti
support
vaccin
develop
pathogen
criteria
combin
multipl
step
perform
propos
assess
criteria
extern
review
subject
matter
expertis
eid
vaccin
develop
conflict
interest
review
select
open
competit
process
basi
demonstr
year
work
clinic
chemistri
manufactur
control
aspect
vaccin
develop
propos
assess
three
five
review
review
receiv
manual
present
provid
detail
descript
criteria
scorecard
templat
instruct
exampl
fill
templat
assist
clarif
provid
respons
specif
question
email
phone
throughout
review
process
criterion
review
ask
defin
like
perform
propos
scale
see
data
detail
order
determin
degre
homogen
assess
provid
differ
review
assess
variabl
test
conduct
specif
criterion
perform
estim
like
follow
step
undertaken
first
perform
mean
across
review
assess
given
propos
calcul
second
differ
mean
review
perform
estim
given
propos
calcul
third
step
repeat
propos
fourth
review
averag
deviat
perform
estim
perform
mean
across
assess
propos
estim
fifth
basi
cicchetti
classif
review
variabl
determin
good
averag
deviat
less
perform
mean
excel
deviat
less
perform
mean
across
assess
propos
seven
review
found
least
one
averag
like
perform
estim
deviat
equival
perform
mean
across
assess
propos
total
estim
deviat
observ
account
total
number
like
perform
estim
collect
impact
remov
result
analysi
test
found
substanti
chang
perform
propos
step
partial
valu
partial
valu
function
elicit
sac
member
use
onlin
survey
respond
survey
recipi
function
defin
use
split
decompos
scale
techniqu
also
known
method
von
winterfeldt
edward
elicit
valu
perform
rang
point
figur
question
procedur
appli
elicit
partial
valu
sac
member
answer
six
pairwis
choic
question
iter
approach
valu
instanc
first
question
consid
follow
two
propos
differ
start
likelihood
gener
vaccin
relev
use
respons
one
cfp
target
pathogen
imagin
given
opportun
improv
perform
one
propos
follow
option
would
prefer
option
improv
propos
likelihood
gener
vaccin
relev
use
respons
one
cfp
target
pathogen
increas
x
option
b
improv
propos
b
likelihood
gener
vaccin
relev
use
respons
one
cfp
target
pathogen
increas
x
indiffer
option
first
question
x
set
perform
rang
respond
indiffer
partial
valu
function
consid
linear
question
ask
respond
chose
option
option
b
valu
x
updat
accord
logic
defin
section
data
pairwis
choic
question
identifi
within
rang
assum
rang
basi
partial
valu
function
could
defin
see
section
data
step
weight
weight
elicit
use
method
von
winterfeldt
edward
case
rang
perform
sac
member
use
onlin
survey
respond
survey
recipi
iter
pairwis
comparison
use
identifi
valu
b
respond
would
indiffer
improv
improv
specif
follow
question
ask
via
onlin
survey
consid
follow
two
propos
would
prefer
propos
gener
vaccin
relev
use
respons
one
target
pathogen
technolog
suitabl
use
vaccin
develop
newli
emergingunexpect
pathogen
propos
b
gener
vaccin
relev
use
respons
one
target
pathogen
technolog
suitabl
use
vaccin
develop
newli
emergingunexpect
pathogen
initi
valu
set
vari
depend
respons
defin
section
data
six
question
valu
b
defin
within
rang
defin
section
data
assum
valu
b
rang
section
data
provid
detail
b
use
estim
weight
step
time
prefer
r
time
prefer
estim
use
choic
exercis
design
identifi
valu
c
sac
member
indiffer
z
chanc
success
deliv
propos
within
year
chanc
within
year
follow
question
format
implement
sac
member
onlin
survey
consid
follow
two
propos
would
prefer
propos
success
complet
z
propos
b
success
complet
valu
z
first
question
set
vari
depend
respons
manner
describ
section
data
six
question
valu
c
identifi
within
rang
describ
section
data
assum
c
took
valu
rang
section
data
provid
detail
c
use
estim
estim
discount
rate
step
uncertainti
review
perform
input
sac
prefer
subject
signific
variat
uncertainti
incorpor
mcda
via
mont
carlo
simul
model
run
time
time
draw
differ
input
follow
perform
input
criteria
iter
randomli
select
one
review
randomli
select
perform
estim
perform
distributionsac
prefer
iter
randomli
drew
partial
valu
weight
time
prefer
singl
sac
member
distributionsth
mean
confid
interv
perform
v
estim
iter
simul
comparison
propos
within
iter
allow
rank
propos
analys
across
iter
allow
estim
rank
probabl
propos
step
report
mcda
variou
iter
model
present
sac
email
teleconfer
valid
practic
util
decemb
juli
detail
methodolog
document
share
juli
model
find
present
sac
decis
meet
august
criteria
perform
vaccin
r
propos
present
tabl
uncertainti
perform
mean
substanti
overlap
confid
interv
around
propos
perform
likelihood
gener
suitabl
vaccin
one
cfp
target
pathogen
likelihood
platform
technolog
suitabl
vaccin
develop
new
pathogen
tabl
present
result
prefer
elicit
survey
greater
weight
attach
perform
particip
remain
particip
gave
equal
weight
perform
particip
discount
rate
high
rate
particip
respons
prefer
survey
impli
partial
valu
function
increas
margin
return
though
small
proport
particip
respons
impli
linear
function
respect
decreas
margin
return
respect
figur
present
overal
discount
valu
propos
rank
propos
similar
overal
valu
except
hand
propos
high
budget
uncertainti
perform
score
prefer
mean
substanti
overlap
confid
interv
around
propos
overal
valu
varianc
observ
figur
explain
variat
review
assess
propos
perform
assum
project
select
figur
plot
likelihood
propos
rank
top
basi
discount
valu
versu
consider
budget
affect
rank
output
analysi
except
two
propos
substitut
top
depend
whether
rank
valu
top
valu
right
blue
dot
line
top
top
purpl
dot
line
figur
figur
demonstr
despit
larg
uncertainti
criteria
perform
stakehold
prefer
clear
propos
rank
emerg
consider
top
rank
likelihood
sac
recommend
margin
deviat
rank
meet
august
sac
present
review
assess
propos
result
mcda
follow
deliber
recommend
propos
fund
propos
recommend
propos
highest
probabl
rank
top
propos
mcda
valu
case
sac
recommend
deviat
analyt
find
sac
deliber
highlight
possibl
reason
diverg
lower
emphasi
believ
request
budget
unrealist
could
substanti
increas
implement
lower
emphasi
place
feasibl
manufactur
scalabl
speed
higher
emphasi
place
use
potenti
new
pathogen
addit
consider
contribut
final
select
recommend
includ
higher
emphasi
target
pathogen
versu
unknown
pathogen
divers
consider
particular
fund
divers
platform
cfp
target
pathogen
figur
plot
top
rank
propos
cumul
valu
cumul
cost
rank
two
differ
way
valu
b
propos
recommend
fund
sac
valu
paper
involv
number
innov
evalu
earli
stage
vaccin
r
candid
eid
address
gap
identifi
previou
literatur
includ
explicit
consider
technic
oper
feasibl
propos
use
expert
review
assess
vaccin
perform
absenc
histor
po
data
propos
multipl
addit
combin
perform
comprehens
list
criteria
assess
overal
valu
propos
compliant
theoret
properti
requir
set
criteria
mcda
marsh
et
al
appli
properti
emerg
particular
decis
context
zeleni
use
adapt
swing
weight
techniqu
elicit
incorpor
stakehold
prefer
assess
overal
valu
propos
use
mont
carlo
simul
account
uncertainti
perform
estim
stakehold
prefer
propos
rank
cepi
invest
eid
vaccin
r
face
signific
uncertainti
potenti
perform
propos
vaccin
preclin
earli
clinic
phase
stakehold
object
evid
mcda
model
input
output
substanti
overlap
confid
interv
overal
valu
propos
nevertheless
use
mont
carlo
simul
reflect
uncertainti
rank
probabl
distinguish
propos
broadli
consist
sac
recommend
sac
decis
meet
august
mcda
find
inform
deliber
individu
propos
perform
comparison
propos
across
diseas
platform
technolog
sac
recommend
howev
correspond
entir
mcda
never
intent
mcda
remov
delib
compon
process
howev
diverg
sac
recommend
model
output
point
lesson
research
also
way
valid
practic
use
model
first
sac
deliber
point
criteria
could
ad
mcda
distribut
invest
across
propos
employ
differ
platform
implic
select
propos
modest
valu
term
combin
perform
across
criteria
ad
desir
platform
divers
cepi
invest
portfolio
second
sac
place
less
emphasi
case
propos
budget
consid
unrealist
one
implic
propos
small
budget
whose
overal
valu
otherwis
low
priorit
third
sac
deliber
point
toward
structur
implic
mcda
novel
combin
model
structur
adopt
mcda
applic
healthcar
multipl
compon
marsh
et
al
despit
concern
health
technolog
assess
meet
analyt
requir
addit
model
marsh
sculpher
caro
tervonen
multipl
compon
model
implicitli
gave
equal
weight
criteria
wherea
sac
deliber
seem
emphas
criteria
other
eg
fourth
sac
recommend
could
impli
altern
weight
use
model
specif
even
greater
weight
given
elicit
survey
weight
model
elicit
use
iter
comparison
improv
pair
criteria
method
chosen
due
small
sampl
size
provid
insuffici
power
discret
choic
experi
desir
elicit
ordin
data
survey
format
tervonen
et
al
result
averag
weight
given
though
also
signific
variat
sac
member
weight
given
variat
one
possibl
would
reconcil
sac
recommend
result
mcda
sac
member
gave
higher
weight
influenti
deliber
conclus
analysi
report
studi
demonstr
possibl
use
mcda
support
priorit
vaccin
r
invest
complex
decis
context
character
outcom
uncertainti
varianc
expect
perform
vaccin
heterogen
stakehold
prefer
intent
aid
rather
replac
delib
stakehold
process
prescrib
decis
find
illustr
mcda
help
differenti
invest
support
decis
make
mr
gougla
report
grant
research
council
norway
conduct
studi
dr
marsh
report
grant
person
fee
research
council
norway
cepi
conduct
studi
work
partli
support
research
council
norway
global
health
vaccin
programm
globvac
project
number
procedur
perform
studi
involv
human
particip
accord
ethic
standard
institut
andor
nation
research
committe
helsinki
declar
later
amend
compar
ethic
standard
articl
contain
studi
anim
perform
author
inform
consent
obtain
individu
particip
includ
studi
